Y-mAbs Therapeutics announces new business units for Radiopharmaceuticals and DANYELZA, reporting preliminary revenues of $88 million for 2024. Y-mAbs Therapeutics, Inc. has announced strategic ...

Y-mAbs announces positive Phase 1 Trial 1001 results for GD2-SADA in cancer, plans further studies with optimized radiohapten "Proteus." Y-mAbs Therapeutics, Inc. announced positive results from the ...

Y-mAbs Therapeutics (NASDAQ:YMAB) stock peaked at $54.1 in late 2020, fueled by high hopes for its cancer treatment, Omburtamab. However, the FDA's 2020 Refusal to File and subsequent Complete ...

A FDA advisory committee has blown a hole in Y-mAbs Therapeutics’ hopes of winning approval for its rare disease drug, delivering a damning 0-16 verdict on the question of whether the company showed ...

Monoclonal antibodies target specific disease molecules. They can help treat cancer, autoimmune disorders, and infectious diseases. Discover what you should know about this therapy. Monoclonal ...

After Y-mAbs Therapeutics won its first FDA approval more than four years ago, the company has faced numerous hurdles on its quest to become an oncology powerhouse. Now, the drugmaker is moving to ...

Microphysiological systems help address the shortcomings of animal models for mAb development, and CN Bio is taking an active role in supporting organizations in switching to an NAMs-based approach.

Y-mAbs reported a net loss for the quarter ended December 31, 2024, of $6.8 million, or ($0.15) per basic and diluted share, compared to a net loss of $1.0 million, or ($0.02) per basic and diluted ...

Y-mAbs reiterated full-year 2025 total revenue, operating expenses, and cash investment guidance, as well as the ability to fund operations as currently planned into 2027. Pfreundschuh announced ...

Y-mAbs Therapeutics is parting ways with its chief commercial officer and putting a new hire in charge of the cancer drug Danyelza. The biotech made the changes, which include “a small adjustment” to ...

The FDA has killed off Y-mAbs Therapeutics’ slim hopes of winning approval for 131I-omburtamab at the first time of asking. Weeks after its advisory committee roundly rejected the candidate, the ...